SLC5A2 and heart failure: The results of the complete-case sensitivity analyses of the composite outcome (HR 0.67; 95% CI [0.51–0.88]) and first hospitalisation for heart failure (HR 0.66; 95% CI [0.46–0.95]) were consistent with the main analysis with lower hazard ratios among SGLT2 inhibitor-treated patients (Fig. 2).